Research Reports Initiation on Healthcare Stocks -- NuVasive, Nevro, Spectranetics, and NovoCure

Oct 06, 2016, 08:31 ET from Chelmsford Park SA

NEW YORK, October 6, 2016 /PRNewswire/ --

This morning, reviews these four Healthcare stocks: NuVasive Inc. (NASDAQ: NUVA), Nevro Corporation (NYSE: NVRO), The Spectranetics Corporation (NASDAQ: SPNC), and NovoCure Ltd (NASDAQ: NVCR). After a few sessions in the red, Wednesday, October 05, 2016, brought some bullish sentiment back as the NASDAQ Composite ended the trading session up 0.50%; the Dow Jones Industrial Average edged 0.62% higher; and the S&P 500 closed up 0.43%. Looking at the broader markets, eight out of nine sectors in the US made it to positive territories at the close of yesterday's session. You can access our complimentary research reports on these stocks now at:


On Wednesday, shares in San Diego, California headquartered NuVasive Inc. recorded a trading volume of 381,510 shares. The stock ended the day 0.41% higher at $66.55. Shares of the Company, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, traded at a PE ratio of 69.25. NuVasive's stock has advanced 0.17% in the last one month, 11.46% in the previous three months, and 27.81% in the past one year. The Company is trading above its 50-day and 200-day moving averages by 2.96% and 21.90%, respectively. Furthermore, shares of NuVasive have a Relative Strength Index (RSI) of 54.09. Visit us today and download your complete report on NUVA for free at:


Redwood City, California headquartered Nevro Corp.'s stock finished Wednesday's session 0.22% lower at $97.92, with a total trading volume of 407,072 shares. Over the past three months and the previous one year, shares of Nevro, which develops and commercializes a neuromodulation platform for the treatment of chronic pain in the US, Europe, and Australia, have surged 25.67% and 104.26%, respectively. The Company's shares are trading above its 50-day and 200-day moving averages by 3.78% and 34.88%, respectively. Nevro's stock has an RSI of 52.04. The complimentary research report on NVRO can be accessed at:

The Spectranetics  

Colorado Springs, Colorado headquartered The Spectranetics Corp.'s stock advanced 1.62%, to close the day at $25.14. The stock recorded a trading volume of 406,611 shares. Shares of The Spectranetics, which together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system, have gained 2.32% in the last one month, 26.08% in the previous three months and 118.80% in the past one year. The Company's shares are trading 3.55% and 37.72% above its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 56.75. Register for free on and download the PDF research report on SPNC at:


On Wednesday, shares in Saint Helier, Channel Islands-based NovoCure Ltd ended the session 5.42% higher at $8.76, with a total trading volume of 224,457 shares. NovoCure's shares have gained 8.96% in the last one month. The stock is trading 5.84% above its 50-day moving average. Moreover, shares of the Company, which develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields, have an RSI of 55.31. Get free access to your research report on NVCR at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA